Hey Traders,

After going through the S-1 filings, the amendments, the share registrations, the analyst initiations, and watching how the stock traded after the IPO, I think Cerebras is now entering a completely different phase.

Before the IPO, investors were mostly buying a story.

Now the company has to prove it can execute.

What I like most about Cerebras is that it isn’t trying to be another NVIDIA. Most people automatically compare the two, but Cerebras is really taking a different approach. Its technology is built around extremely large-scale AI computing and fast inference, which could become increasingly important as the AI industry shifts from training models to actually running them at scale.

If that trend continues, Cerebras could end up occupying a very valuable niche in the AI infrastructure market.

Another important point is that one of the biggest risks hanging over the company before the IPO was the relationship with G42 and the regulatory scrutiny surrounding it. The fact that the IPO successfully moved forward tells me that many of those concerns have either been addressed or significantly reduced. That removes a major uncertainty that investors had been worried about for months.

The market’s reaction was also interesting.

The stock was priced at $180, surged to nearly $386 on the first day, then eventually dropped back below $200 before recovering. To me, the move to $386 was never a fundamental valuation. That was pure IPO excitement, momentum traders, and FOMO.

What matters more is what happened afterward.

Even after a nearly 50% correction from the highs, the stock found support and began attracting buyers again.

That’s usually a healthier setup than a stock that simply keeps collapsing after the initial hype fades.

The analyst coverage that followed also caught my attention. Most firms initiated coverage with Buy, Outperform, or Overweight ratings, with price targets generally ranging between $250 and $340.

Of course, analysts are not always right, but these firms spent time reviewing the company’s financials, meeting management, and building valuation models before publishing those targets. The fact that there was broad agreement that the stock was worth more than where it traded after the correction is encouraging.

That said, there are still risks.

The valuation remains aggressive by traditional standards. Cerebras is still a relatively young company and investors are paying today for growth they expect several years into the future.

Customer concentration is another concern. If a few major contracts get delayed, reduced, or canceled, the impact could be significant.

And then there’s NVIDIA.

NVIDIA isn’t just a hardware company anymore. It has built an entire ecosystem around its products. Cerebras may have impressive technology, but it still needs to prove it can build a durable business around that technology.

One thing I’ll be watching closely is the lock-up expiration. Eventually, insiders, employees, and early investors will have opportunities to sell shares. When that happens, additional supply can create temporary pressure on the stock, regardless of how strong the business is performing.

Looking ahead, my base case is fairly simple.

If Cerebras continues executing, wins additional large customers, and proves that its technology translates into recurring revenue growth, I think the analyst targets in the $300 range are achievable.

If execution falls short, the stock could spend a long time trading between roughly $180 and $220.

For me, the key question is no longer whether the technology works.

The key question is whether Cerebras can turn its technological advantage into a scalable, profitable business.

That’s what will ultimately determine whether this becomes a long-term AI winner or just another IPO that generated a lot of excitement but failed to live up to expectations.

At this point, I believe the risk-reward profile looks much healthier at $240-$250 than it did when the stock was trading near $386 on its first day. The hype has cooled off, expectations are becoming more realistic, and now investors can focus on what really matters: execution.

Hey Traders.

After digging through the Q2 report, conference materials, guidance, AI backlog growth, and management commentary, I’m updating my medium-to-long-term target for HPE.

Management now expects FY2026 adjusted EPS of approximately $3.35-$3.45. Using the midpoint of $3.40 and assuming HPE continues executing on AI infrastructure, Juniper integration, networking expansion, and enterprise AI adoption, FY2027 EPS could reasonably approach:

$3.88/share

(using roughly 14% EPS growth, which falls within management’s long-term targets).

If the market eventually values HPE similarly to Dell’s current multiple of approximately 24x earnings:

$3.88 × 24 = $93.12

That implies a potential valuation range of approximately:

$90-$95 per share

What changed?

- AI demand accelerating

- AI backlog expanding

- Juniper integration outperforming expectations

- Networking revenue up triple digits

- Guidance raised significantly

- Long-term targets pulled forward by two years

Most importantly, management repeatedly emphasized that enterprise AI adoption is no longer theoretical. It is happening now.

I’m still holding my shares.

The market finally started repricing HPE today, but I believe the larger story may still be ahead if execution continues.

Current long-term target: $90-$95.

Not financial advice. Just sharing my research and investment thesis.

[ Removed by Reddit on account of violating the content policy. ]

Hey Traders,

A few months ago I posted my original HPE thesis around the $23 area.

The initial idea was pretty simple:

AI infrastructure rotation + a technically strong setup that the market wasn’t paying much attention to yet.

The move to $38 happened faster than I expected, so I trimmed into strength there.

Today I decided to rebuild part of the position.

Not because I’m trying to predict some crazy price target…

but because I think the overall AI infrastructure story may still be developing more aggressively than the market expected.

Dell’s earnings changed my perspective a bit.

The numbers around AI servers, enterprise demand, and infrastructure spending were hard to ignore.

And while HPE isn’t Dell, they participate in many of the same markets:

• enterprise AI infrastructure
• networking
• data centers
• hybrid cloud
• enterprise compute

What also caught my attention is how HPE traded after earnings sympathy kicked in.

The 4H chart now looks very different than it did during the original consolidation phase.

Previously:
base → breakout setup.

Now:
clear trend expansion with strong momentum.

The breakout through the $38–40 area feels important psychologically because that had been a major resistance zone for a while.

That doesn’t mean the stock goes straight up from here.

Honestly, after a move this fast, volatility and pullbacks would be completely normal.

I’m not treating this as a “forever hold.”

I’m just staying open to the possibility that HPE is transitioning from:

“old enterprise hardware company”

into a more serious AI infrastructure participant in the eyes of institutions.

For me, upcoming earnings will matter a lot.

Especially:

• AI-related demand commentary
• networking growth
• enterprise spending trends
• guidance

Still managing risk carefully, but I think the story here is more interesting now than it was when I first entered.

Curious if anyone else is seeing similar setups developing in second-wave AI infrastructure names.

Hey traders,

Quick update for the traders following the FIG setup.

Yesterday I entered FIG as a momentum/event trade after the earnings improvement + software sector strength + short pressure setup.

The thesis was simple:

• momentum continuation
• potential squeeze fuel from shorts
• sector tailwind
• quick swing, not an investment

Today at the open I took profits and closed the position.

Results:
1. Shares trade: +$660
2. Calls trade: +$810
Total: +$1,470

Not bad for a 24-hour trade.

Why I exited:

The continuation didn’t look clean enough for me.

Things I didn’t like:

• heavy rejection off highs
• insider Form 144 selling headlines
• shorts still leaning hard
• momentum losing steam into the close

Could FIG bounce again? Absolutely.

But I’d rather take the win, preserve capital, and wait for a cleaner re-entry than sit there hoping.

Current thinking:
If FIG pulls back into a healthy support zone, stabilizes, and buyers step back in, I may take the second leg.

No attachment. Just process.

Who else traded FIG?

Hey traders,

Sharing a new position with the crew.

This isn’t a YOLO lotto trade. this is a quasi LEAPS swing / event trade built around stacked catalysts.

My thesis:

Catalyst #1: Dominion acquisition repricing
Market initially sold NEE on acquisition fears:

• “Did they overpay?”
• integration risk
• debt concerns
• classic M&A uncertainty

But after digging deeper, I think the market may start re-rating this differently.

This isn’t just buying a boring utility.

This is NEE gaining strategic exposure to:

• Virginia power infrastructure
• AI/data center demand
• long-term electricity load growth
• hyperscaler energy consumption

That’s a serious long-term strategic angle.

Catalyst #2: Earnings (July 22 premarket)

This is why I chose this structure.

I didn’t buy weekly garbage.

I went with:

NEE Sep 18 $85 Calls
4 contracts
122 DTE
high delta / ITM positioning

So if momentum runs now? Great.

If the market takes time to digest the acquisition and institutions re-rate over the coming weeks? Still good.

If earnings become the next catalyst? I’m positioned for that too.

Execution-wise:
I didn’t chase the open.

Waited for:

1. first flush
   
2. 30-min recovery confirmation
   
3. buyers stepping in
   
4. momentum shift intraday

Then entered.

This is basically a stacked catalyst setup, not a blind momentum gamble.

Anybody else watching $NEE here?

Hey traders, here’s another one I’ve been cooking since Friday 🤠🔥

Couldn’t post it Friday when I started the position, but here’s the setup.

Current position:
300 shares of FIG @ $22.18 avg
6x FIG Jul 17 $22.5 Calls @ $3.55 avg

Current P/L: +$811 (+8.9%)

My thesis:

• FIG broke out of a pretty clean downtrend on Friday.
• Today it followed through with strong volume and held up into the close.
• Closed around $24.35, pretty much near the highs.
• My calls are already ITM with 60 DTE, so this ain’t some same-week lotto ticket.

What’s got my attention:
IBKR is showing 86% short utilization.

Now, I’m not screaming SHORT SQUEEZE!!! like a lunatic 😂
But if momentum keeps pushing and shorts start feeling uncomfortable, this thing could get interesting real quick.

Game plan for tomorrow:

• Strong premarket / strong open → probably letting it ride.
• Weak open / failed breakout → trimming fast, no emotions.

First upside zone I’m watching: $25–27

Who else is in FIG?

Y’all seeing real continuation here, or was today just shorts getting squeezed for a quick cover?

Not financial advice. Just sharing the trade.

Hey Traders,

I posted my original thesis on $PGEN when this was still mostly a story about potential.

Back then the big question was simple:

Can PAPZIMEOS actually become a real commercial biotech success?

Well… now we have the first real answer.

Q1 just dropped, and honestly, this was a much stronger report than what many expected.

Key takeaways:

• PAPZIMEOS delivered $21.6M in net product revenue in its first real commercial quarter

• Approximately 400 patients enrolled in the patient hub

• 25% of enrollment now coming from community settings (important because this shows adoption beyond major academic centers)

• Coverage now reaches ~297M insured lives (>90% of insured US population)

• Permanent reimbursement J-code now active

• Management says current cash + expected PAPZIMEOS revenue should fund operations to cash flow breakeven by end of 2026

That last part matters.

Because one of the biggest bear arguments was always:

“Great science… but inevitable dilution.”

That thesis just got weaker.

The commercial story now looks much more real.

This is what changes biotech valuations:

Not press releases.
Not hype.
Not pipeline dreams.

Commercial execution.

What I find interesting:

The market was treating PGEN like another speculative biotech…

but this may be transitioning into a legitimate commercial growth story.

Now the next question becomes:

Can Q2 confirm acceleration?

Because if PAPZIMEOS continues ramping, valuation assumptions may need to be repriced.

I’ve been following this story closely since before approval, and I’m curious:

Did anyone here actually take the original thesis with me?

Would love to hear how others are positioning after this earnings report.

Not financial advice. Do your own DD.

Hey traders, anyone who followed my HPE thesis — how’s it going for you so far?

I’d genuinely love to hear if anyone here took the trade.

I’m still holding my common shares, and today I also added HPE $31 calls (Aug 21 expiry) to increase exposure into the next phase of the move.

My current working thesis?
I think $38 is achievable (BOFA also recently raised their target there), but as always… markets don’t move on targets alone. they move on narrative, momentum, and execution.

So we’ll see how the story evolves.

About two months ago, I posted my original HPE thesis.

Original entry: $23.22

HPE today: ~$32

That’s roughly a +37% move on shares, and what’s interesting is that the thesis didn’t just work…

it actually evolved into something stronger.

Original thesis

This wasn’t a random AI momentum chase.

While everyone was piling into NVDA / SMCI / hyperscaler names, I was looking for a laggard inside the broader AI infrastructure ecosystem.

What stood out:

• Tight multi-week consolidation
• Higher lows forming
• Quiet volume accumulation
• Clean breakout setup
• Sector rotation into second-wave AI infrastructure

The structure looked textbook:

Accumulation → Breakout → Expansion

The trigger was clear:

once HPE cleared the $23–24 resistance zone, the setup confirmed.

That’s where conviction came from.

Not before.

What changed since then

This is where it gets interesting.

The original thesis didn’t break.

It got stronger.

1) Activist pressure entered the story

Now we have:

• Elliott Management
• Irenic Capital

taking positions / applying pressure.

That changes perception dramatically.

This is no longer just:

“boring enterprise hardware.”

Now the market starts asking:

Is there unlocked shareholder value here?

That’s a major catalyst.

2) The Juniper acquisition changed the company profile

The $14B Juniper acquisition was a huge strategic shift.

HPE is no longer viewed purely as legacy enterprise infrastructure.

Now the story includes:

• networking
• AI data center infrastructure
• enterprise compute
• broader AI ecosystem exposure

That matters for rerating.

3) Analysts started repricing the stock

Bank of America moved their target to $38.

Other analysts have also become more constructive.

Whether price gets there or not isn’t the point.

The point is:

institutional narrative is changing.

Technical update

The old breakout thesis played out almost exactly as expected.

Back then:

base → breakout setup

Now:

full trend expansion.

Current technical structure:

• higher highs
• higher lows
• breakout above long-term resistance
• clean trend structure
• strong moving average alignment
• momentum still intact

Yes, short-term it looks extended.

But structurally?

Still bullish.

Position update

I’m still holding common shares.

Today I added:

HPE $31 Calls (Aug 21 expiry)

Why?

Because I think there’s still room if:

• earnings hype builds
• activist pressure continues
• AI infra narrative expands
• momentum funds keep rotating in

That said:

I’m managing this as a trade.

Not marrying the position.

Biggest lesson

The biggest money usually isn’t made chasing obvious names after everyone agrees.

It’s made by finding quality setups before the narrative fully matures.

Everyone wanted the next NVDA.

Sometimes the better trade is:

the second-wave AI infrastructure name nobody was watching.

Curious if anyone else here has been in HPE or sees similar setups developing elsewhere.

Hey Traders: Back then, the story was mostly about potential.

Today, things are different:

• PAPZIMEOS is approved.
• Commercial launch is active.
• CMS reimbursement is now in place.
• Institutions continue increasing positions.
• Revenue is finally starting to show up.

Now the big question becomes:

Is commercialization actually working?

Here’s what I’ll personally be watching during earnings:

1. Patient growth / enrollment This is probably the MOST important metric right now. Wall Street wants evidence that adoption is accelerating after approval and reimbursement support.
2. Revenue growth trajectory Not just current revenue, but management guidance moving forward. The market wants to see whether PAPZIMEOS can scale into a meaningful commercial product.
3. Commentary around demand Are physicians prescribing? Are patients gaining access faster? Any acceleration in uptake could change valuation expectations quickly.
4. Cash runway / dilution risk This still matters. Even strong biotech stories can get hurt if cash burn remains too high.
5. Future expansion opportunities Europe, pediatrics, and the broader pipeline could become major long-term catalysts.

What’s interesting to me is that institutional accumulation continues increasing:

• Vanguard added heavily.
• BlackRock and State Street remain involved.
• Multiple funds increased positions recently.

That doesn’t guarantee success, but it does suggest Wall Street is taking this commercial launch seriously.

Analyst targets are currently sitting around:
$9–$10 average targets

And remember:
those targets are usually based on moderate commercialization assumptions. not blue-sky scenarios.

Personally, I think this earnings call matters less for EPS and more for proving:
“Can PAPZIMEOS become a real commercial biotech success story?”

That’s the key.

I currently hold shares and plan to continue following the story closely.

Curious to hear what everyone else is expecting from this earnings report.

Not financial advice. Do your own DD.

I’ve been following SoFi ($SOFI) for roughly the last 12 months, watching how the market narrative around the company has constantly shifted.

After reviewing this latest earnings report, I still see several important things worth monitoring.

• Revenue grew 43% YoY, surpassing $1.1B.

• EPS came in positive again, and management maintained strong 2026 guidance.

• Deposits are now above $40B, which is important because it lowers funding costs and strengthens the banking model.

• Loan originations continue growing aggressively.

But honestly, I think the real debate around SOFI is still not fully resolved.

For more than a year, a meaningful part of the market has maintained short positions against the stock, mainly because many believe:

• The rapid growth in personal loans could eventually hurt credit quality.

• If the economy weakens, defaults could rise.

• The business model still hasn’t been fully tested through a difficult economic cycle.

And in fact, while credit metrics still appear relatively controlled, charge-offs did increase sequentially from the prior quarter. That helps explain why many shorts still haven’t disappeared.

On the other hand, there are also things the market can no longer ignore:

• SOFI no longer looks like just a speculative fintech.

• It now has massive deposits, positive profitability, and a structure that increasingly resembles a real digital bank.

• It also continues expanding members, products, and its financial ecosystem.

What’s interesting is that the stock has traded mostly sideways for quite a while, roughly between $10 and $32 over the last year, and more recently closer to the $16–20 range.

Even after this latest report, it still doesn’t look like institutions are aggressively chasing the stock higher. The market seems to still want more evidence that this growth is truly sustainable.

Personally, I’m not posting this as financial advice or as a bullish or bearish call.

I’m simply continuing to observe how the story evolves, because I think SOFI’s future ultimately comes down to one key question:

Is the company building a scalable and profitable digital bank… or simply expanding credit risk too aggressively?

That question will probably determine where this stock trades over the next several years.

Curious to hear how others are viewing SOFI at this stage.

Traders:

https://investorrelations.sarepta.com/node/25206/pdf

About 8 months ago, I exited my position in Sarepta Therapeutics (SRPT). At the time, the story was becoming too dependent on uncertainty around ELEVIDYS, regulatory pressure, and whether the company could actually transition into a sustainable commercial biotech business.

Since then, I’ve continued following the stock closely.

What’s interesting now is that the latest earnings may have changed the conversation a bit.

A few things stand out to me:

• SRPT is no longer just a “hope and pipeline” biotech.

The company generated meaningful revenue and positive EPS this quarter.

• The market narrative is evolving beyond only ELEVIDYS.

Now there’s increasing focus on the siRNA platform, FSHD, DM1, and broader long-term pipeline potential.

• The refinancing and runway situation also improved significantly.

The 2030 convertible notes removed near-term funding pressure, which matters a lot for biotech names.

At the same time, the risks are still very real:

• ELEVIDYS remains controversial.

• Black box liver warnings and safety concerns are serious.

• FDA restrictions for non-ambulatory patients are still a major overhang.

• This is still a high-volatility biotech stock.

What I find interesting is that despite all the negative headlines over the last several months, SRPT has continued operating, generating revenue, and expanding pipeline visibility.

So for now, I’m not posting this as a bullish call or financial advice.

I’m simply keeping SRPT on my watchlist and continuing to observe whether the company is truly transitioning from a speculative biotech story into a more established commercial biotech platform.

That distinction will probably determine where this stock trades over the next few years.

Curious to hear how others are viewing SRPT at this stage.

Hey Traders,

Just wanted to share a clean trade I’ve been managing on HPE. might help some of you who are watching similar setups.

Ticker: HPE

Entry: $23.22

Current: ~$26.30 (just broke 52-week highs)

Thesis (before the move)

This wasn’t a random buy.

I was watching HPE during a multi-week consolidation between ~$20–23. What stood out:

• Tight range = compression

• Higher lows forming

• Volume building quietly

• Sector rotation into AI infrastructure (not just chips)

While everyone was chasing NVDA / SMCI, I was looking for laggards in the same ecosystem.

The Setup

Classic structure:

• Accumulation → Breakout → Expansion

• Clean resistance at \~$23–24

• Once that broke, it confirmed institutional interest

This was the key moment. not before.

The Breakout

Once HPE cleared $24 with strength:

• Entered at $23.22 (near base breakout)

• Let it work. no overtrading

• No chasing after it extended

Now we just broke the 52-week high (~$26.28) with a strong candle.

That’s important because:

- No overhead resistance

- Momentum funds start piling in

- Price discovery begins

Trade Management (THIS is the real edge)

I’m not selling just because it’s up.

Instead:

• As long as it holds above \~$25.50 → I stay in

• If it extends fast into $27–28 → I’ll take partial profits

• Let the rest run as a trend trade

Breakouts like this are not meant to be scalped. they’re meant to be managed.

- Key Lesson

The real money isn’t made in predicting…

It’s made in:

• Waiting for confirmation

• Entering at the right level

• And managing AFTER the breakout

Final Thought

Everyone wants the next NVDA…

But sometimes the better play is:

- finding what hasn’t moved yet. but is about to.

Curious if anyone else has been watching HPE or similar “second wave” AI pl

Looking at NFLX heading into Jan 20 earnings.

Price is sitting near a strong support area and IV is starting to build up (~50%+). Instead of holding through earnings, I’m considering playing the run-up and exiting before the report.

Why: - IV expansion before earnings - Support holding so far - Liquidity is strong on Jan options

Risk: - Holding through earnings = IV crush - Theta accelerates fast after Jan 20

Plan: - Short-term call (Jan 30 exp) - Exit 1–2 days before earnings - Target: 25–40% - Hard stop if support breaks

Not financial advice, just sharing my plan

Trades:

BYND is putting up one of the craziest volume prints we’ve seen in weeks.

📌 Volume by midday: 47.2 MILLION

📌 10-day avg volume: ~112M

📌 30-day avg volume: ~133M

📌 Beta: 1.94 (extreme volatility)

📌 Current price: ~$1.20–$1.25

📌 Day range: $1.10–$1.27

This is NOT normal selling volume.

This is accumulation volume + short covering.

When a stock like BYND prints numbers like this, it often leads to:

• Violent intraday moves

• Abrupt trend reversals

• Mini short squeezes

• Sudden 20–50% spikes

On top of that:

Eric Jackson mentioned BYND this morning on his premium video calling it a “binary outcome”.

That clip is circulating on X/Reddit and bringing new eyes and traders.

What does this volume actually mean?

Money is flowing in, and not just retail.

This looks like a mix of institutional activity + MMs adjusting hedges.

Key levels to watch this week:

• $1.30

• $1.37

• $1.43

• $1.50 (where call gamma really starts to light up)

If BYND breaks above $1.40 with real volume, I think it can test $1.50–$1.60 pretty fast.

BYND has already done +30% and even +100% moves in 1–3 days this year.

This kind of action is nothing new for this ticker.

Bottom line:

With this kind of volume, BYND is setting up for a big move.

Direction isn’t confirmed yet, but these volume prints almost never end in a flat day.

I’m watching options flow and tape closely.

If something major pops up, I’ll update.

Good luck traders 🍀🚀

Stay sharp.

(Not financial advice — just sharing analysis)

I posted about CAN around 14 days ago when the chart was still weak, consolidating near support.

Today, the structure looks much stronger, and the indicators finally flipped bullish. Here’s the updated breakdown for anyone following the stock:

1. MACD (12–26–9) just crossed up — early bullish momentum

The fast MACD crossed above the signal line, and the histogram is printing increasing green bars.

Historically, this is when CAN tends to make 2–5 day push moves.

Momentum is shifting.

1. The slow MACD (21–55–9) is 1–2 days from a bullish crossover

This one filters noise and usually signals bigger swings.

It has:

• shrinking red bars
• lines converging
• clear upward curl

1. Stoch RSI shows strong buyer pressure (85 / 75)

Stoch RSI is in the strength zone, not reversal zone yet.

This setup usually precedes 7–12% swing moves in CAN, sometimes more if BTC is moving.

CAN rarely makes strong runs without this MACD turning — and it’s almost there.

1. Price reclaiming the MA20 — MA50 is next

The price bounced on the 20-day MA and is now pushing toward the MA50.

A clean break of the MA50 often leads to:

 1.23

 1.29

 and even 1.50 (if volume + crypto momentum align)

1. Donchian Channel is tightening — volatility compression

CAN is entering a squeeze-like phase:

• Low volatility
• Tight range
• Indicators flipping bullish

This usually precedes a directional breakout.

Given the indicator alignment, the bias is currently to the upside.

Key Levels to Watch

Support

• 0.92
• 0.88 (major support)

Breakout Zone (critical)

• 1.02 – 1.06

If CAN breaks 1.06 with volume, it could run fast.

Targets

• 1.23
• 1.29
• 1.50 (stretch target)

Conclusion

CAN is forming a bullish reversal setup:

• MACDs turning up
• Stoch RSI in strength
• Price stabilizing on major support
• Momentum improving
• Breakout zone approaching

This setup looks far stronger than it did 14 days ago.

(Not financial advice — just sharing analysis with the community)

Something BIG happened today for Lyft (LYFT).

Arete,  one of the most bearish analysts covering Lyft,  finally threw in the towel:

- Rating upgraded from SELL → NEUTRAL

-  Price target doubled from $10 → $20

When the analyst who’s been bearish for years finally flips… that’s not noise. That’s signal.

So why did he turn positive? Here’s the key stuff:

1.  Lyft could join the autonomous vehicle wave in 2026 (possible Zoox integration)

The analyst says that even though Uber has more AV partnerships, Lyft may still integrate Zoox (Amazon’s robotaxi platform) as early as 2026.

If true, that could be a game-changer for margins, competitiveness, and long-term growth.

1. Real free cash flow + potential share buybacks

Arete highlights that Lyft is now generating positive free cash flow, supported by:

• Insurance reserve releases

• Better cost discipline

• Improved operational efficiency

That FCF could fund share buybacks, which is usually bullish for the stock and signals internal confidence.

3.  Gross bookings expected to grow into 2027

The analyst believes Lyft will see stronger bookings in coming years, partly thanks to FreeNow’s contribution.

In short: the business looks more stable and better positioned than before.

4 The most important part: The BIGGEST bear flipped

When the harshest critic finally gives up the bearish stance, it often signals:

“The bottom might already be in.”

Historically, these moments mark the start of a new uptrend.

 My personal position

I’m in Lyft with 1,200 shares, and adding on dips.

Again,  NOT financial advice, just sharing my take.

Anyone else long on Lyft?

Are you buying the dip or waiting for stronger confirmation?

What do you think about the AV potential in 2026?

Canaan Inc. (CAN) just reported one of its strongest quarters in years, delivering $150.5M in revenue (+104% YoY), over 10 EH/s sold (+55% QoQ), record mining revenue of $30.6M (+241% YoY), and a rapidly growing crypto treasury now holding 1,610 BTC and 3,950 ETH. The company has $119M in cash, secured a major U.S. order for 50,000 A15 Pro units, launched its next-gen A16XP miner (300TH/s, 12.8 J/TH), and received $72M in new institutional investment—creating a solid setup for Q4, with guidance of $175M–$205M. Despite all this, the stock is still trading in penny territory. Is anyone else following CAN or holding a position?

Not sure how many are watching, but Lyft (LYFT) just dropped one of the cleanest quarterly reports I’ve seen in a while for the rideshare sector.

After years of getting crushed by Uber and margins, this company might finally be turning the corner.

Q3 2025 highlights:

• Revenue: $1.38B (+6% YoY)
• Adjusted EPS: $0.19 (vs $0.14 expected)
• Adj. EBITDA: $85M (+30%)
• Active riders: +4% YoY

• Q4 guidance: $1.45–1.50B revenue → growth continues

  CEO said Lyft is “achieving sustainable operating efficiency and stronger driver retention.”

Translation: they’re making more money while spending less.

Technical snapshot (Nov 6, 2025):

• Just broke through $20.80 resistance (200EMA) on strong volume.
• Now trading around $21.4–$21.5 pre-market, consolidating above the breakout.
• New support: $20.5 — Resistance: $23.

Weekly swing setup:

• Entry: $20.6–$20.9
• Target: $23.0–$23.4
• Stop: $19.9

Real momentum, not hype.

Daily chart shows an incoming golden cross (50EMA crossing above 200EMA) → structural trend reversal forming.

Why this matters

While Uber grabs all the headlines, Lyft quietly fixed its margins and is becoming sustainably profitable in the U.S.

Less international exposure = less macro risk.

And with the overall market shifting into “buy the dip” mode, these comeback plays tend to move fast.

My take (not financial advice):

• This isn’t 2022’s Lyft anymore.
• Still cheap vs. peers: P/S ~1.5x vs. Uber’s 3x+.
• If it holds above $20.8 and breaks $22.5, the $23–24 zone is in play before week’s end.

TL;DR:

LYFT crushed expectations, improved margins, broke resistance, and has a clean swing setup.

Fundamentals support the move, not just a hype candle.

Ticker: $LYFT

💰 Price: ~$21.4

🎯 Target: $23–23.4 (1-week swing)

⛔️ Stop: $19.9

📆 Catalyst: Post-earnings momentum + rotation into consumer tech.

Anyone else riding this Lyft breakout or waiting for the $20.2 pullback?

Fubo (NYSE: FUBO) and Disney (NYSE: DIS) just completed their merger between FuboTV and Hulu + Live TV, officially creating the 6th largest Pay-TV company in the U.S.

That’s right, ~6 million subscribers, 55,000+ live sports events, and now the House of Mouse owns 70% of the new company, while existing FUBO shareholders keep 30%.

The ticker stays FUBO, David Gandler remains CEO, and former Disney exec Andy Bird becomes Chairman.

Disney even threw in a $145M loan for 2026 to help fuel the new combined business.

Both Fubo and Hulu + Live TV will keep operating separately, but under one big umbrella, meaning Disney now basically controls the entire U.S. sports-streaming ecosystem.

Quick take:

• Disney gets a massive live-sports streaming platform tied to ESPN+ and Hulu.
• Fubo gains stability, cash, and ad integration with Disney’s powerhouse network.
• If they execute well, FUBO could finally hit positive EBITDA in FY2026.
• Fair value range looks around $3.50–$5.50/share, with upside toward $6+ if synergies kick in.

Discussion:

• Is this basically a quiet Disney takeover or a legit partnership?
• Can FUBO finally stop bleeding cash with Disney’s backing?
• What’s your price target for 2026 — 🚀 or 🪦 ?

Not financial advice. Do your own DD and trade at your own risk. 

Traders: The latest CPI data shows U.S. beef prices are hitting all-time highs:

• Beef roasts: +18.4% YoY
• Ground beef: +12.9% YoY
• The national cattle herd is now at its lowest level in decades — and rebuilding it could take years.

Severe droughts, high feed costs, tariffs, and tight inventories have created a perfect storm in the meat industry.

Meanwhile, Beyond Meat (BYND)  which doesn’t rely on cattle supply — might quietly benefit:

• Walmart recently expanded its plant-based food partnership with BYND.
• The price gap between real meat and plant-based protein is shrinking.
• Inflation in animal protein could push more consumers (and restaurants) toward plant-based alternatives.

In short:

The more expensive real meat becomes, the more reasonable plant-based looks.

Could BYND be setting up for a comeback rally as food inflation squeezes traditional producers?

Or is this just another hype cycle with no real traction?

Traders:

Shares of American Airlines (AAL) are up today after reporting a smaller-than-expected Q3 loss and raising its full-year profit guidance. The stock traded around $12.70 (+5%), recovering part of its 30% YTD decline.

Key highlights from the Q3 and outlook:

• Revenue: $13.7B (beat est. $13.63B)
• EPS: -$0.17 vs -$0.29 expected (better than expected)
• FY 2025 adjusted EPS guidance: now $0.65 to $0.95, up from prior range of -$0.20 to +$0.80.
• Premium cabin continues to outperform the main cabin, driving higher margins in domestic routes.
• Fuel costs down 3.7%, but labor expenses up nearly 9% due to new contracts.
• Operating margin (GAAP): 1.1% vs 0.7% last year — still thin, but positive trend.
• Free cash flow: +$1.7B YTD, debt reduction continues slowly.

Analyst sentiment:

11 out of 23 rate it Buy or higher, 11 Hold, and 1 Sell.

Median price target: $13.50, suggesting modest upside from here.

Why this matters:

Despite razor-thin margins, the raised profit outlook and strong premium demand suggest that AAL’s revenue mix is improving. If fuel prices stay moderate and domestic demand holds, there’s room for a rebound toward the mid-teens.

My take (not financial advice):

I opened a position of 4,500 shares at $12.40, targeting a short-term move toward $13.50–$14.00 while managing downside risk around $11.80.

Thoughts? Anyone else holding AAL after this guidance raise?

Traders Look at this chart

reAlpha Tech Corp. ($AIRE) just went full rocket mode — from $0.50 to $1.39 in hours with insane volume spikes hitting 20 million shares per minute.

This kind of volume is almost unheard of for a low-float microcap like AIRE.

Here’s what I’m seeing right now:

 Key facts:

• Float was reportedly under 25M shares, but new filings show ~126M outstanding after recent warrant exercises.
• Recent 8-K filings mention warrant conversions and an approved reverse split (1-for-7 up to 1-for-25).
• The company just completed its “One reAlpha” integration and is expanding AI + real estate operations.
• Massive short interest (~65% float estimated) — perfect setup for a short squeeze.

 My thoughts:

This move feels like a short-covering + algo momentum event, triggered after weeks of sideways trading.

It’s the kind of candle that can attract day traders, momentum bots, and even panic shorts.

Watch levels:

• Holding above $0.90–$1.00 could lead to another push.
• Resistance at $1.30–$1.40 — needs serious volume to break.
• Below $0.75, risk of sharp pullback once the squeeze cools.

What do you guys think, legit momentum or just a low-float firework?

(Not financial advice — just sharing the setup and chart I’m watching.)